MBX Biosciences, Inc.
In the quarter to June 2026, EPS fell 34.5% and free cash flow fell 29.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow MBX
MBX Biosciences, Inc. (MBX) Piotroski F-score
Piotroski F-score, annual
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|
How the score is made up
There are no annual figures to work it out from.
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | 8 |
| ADMA ADMA Biologics Inc compare | 5 |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 4 |
| BEAM Beam Therapeutics Inc. compare | 4 |
| PGEN Precigen, Inc. compare | 3 |
| NAMS NewAmsterdam Pharma Company N.V. compare | 3 |
| CLDX Celldex Therapeutics, Inc. compare | 2 |
| SLS SELLAS Life Sciences Group, Inc. compare | 2 |
| MBX MBX Biosciences, Inc. | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover